Seres Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Seres Therapeutics, Inc. reported a quarterly adjusted loss of $1.63​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 94 cents. The mean expectation of two analysts for the quarter was for a loss of 100 cents per share. Wall Street expected results to range from $-1.34 to -67 cents per share.

• Revenue rose 68.9% to $593.00 thousand from a year ago; analysts expected $6.35 million.

• Seres Therapeutics, Inc.'s reported EPS for the quarter was a loss of $1.63​.

• The company reported a quarterly loss of $16.29 million.

• Seres Therapeutics, Inc. shares had fallen by 41.5% this quarter and lost 86.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Seres Therapeutics, Inc. is $17.00, about 88.5% above its last closing price of $1.96

This summary was machine generated from LSEG data November 4 at 01:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)